The understanding of personalized androgen deprivation therapy
Thomas Keane, MD provides a presentation concerning the personalization of androgen deprivation with reference to prostate cancer patients. The discussion includes recent data that elevates the discussion on the impact of the agonist or the antagonist used in ADT for men with cardiac conditions, obesity, significant LUTS, and closes on an algorithm for personalized ADT treatment.
Thomas E. Keane, MBBCh, FRCSI, FACS, is Professor and Chairman of the Department of Urology at the Medical University of South Carolina in Charleston. Dr. Keane specializes in managing prostate, bladder, and renal cancers.
An avid researcher, Dr. Keane has served as principal investigator or coinvestigator on more than 20 major clinical and preclinical studies, funded by grants from the National Institutes of Health as well as industry-funded. Much of his work focuses on innovative concepts in translational research, including utilizing human tumor xenografts to investigate the efficacy of new therapies as they relate to GU malignancies with particular reference to cytotoxic agents, sphingolipids, and boron-containing compounds. He holds a U.S. patent for sphingolipid derivatives and their use.